Medpace Holdings, Inc. (MEDP)
USD 331.0
(-5.02%)
USD 331.0
(-5.02%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 187.68 Million USD | 22.08% |
| 2022 | 153.74 Million USD | 18.68% |
| 2021 | 129.54 Million USD | 15.99% |
| 2020 | 111.68 Million USD | -5.7% |
| 2019 | 118.43 Million USD | 3.45% |
| 2018 | 114.48 Million USD | 4.23% |
| 2017 | 109.83 Million USD | -8.18% |
| 2016 | 119.62 Million USD | -5.45% |
| 2015 | 126.51 Million USD | -1.57% |
| 2014 | 128.53 Million USD | 95.86% |
| 2013 | 65.62 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 56.73 Million USD | 36.87% |
| 2024 Q2 | 41.45 Million USD | -18.84% |
| 2024 Q1 | 51.07 Million USD | 3.21% |
| 2023 Q3 | 48.28 Million USD | 5.14% |
| 2023 Q2 | 45.92 Million USD | 4.41% |
| 2023 Q1 | 43.98 Million USD | 11.92% |
| 2023 FY | 187.68 Million USD | 22.08% |
| 2023 Q4 | 49.48 Million USD | 2.49% |
| 2022 Q3 | 41.2 Million USD | 6.31% |
| 2022 Q1 | 34.47 Million USD | 4.06% |
| 2022 FY | 153.74 Million USD | 18.68% |
| 2022 Q4 | 39.3 Million USD | -4.63% |
| 2022 Q2 | 38.76 Million USD | 12.43% |
| 2021 Q1 | 30.82 Million USD | 10.64% |
| 2021 FY | 129.54 Million USD | 15.99% |
| 2021 Q2 | 32.2 Million USD | 4.46% |
| 2021 Q4 | 33.12 Million USD | -0.75% |
| 2021 Q3 | 33.38 Million USD | 3.65% |
| 2020 Q3 | 27.73 Million USD | 4.63% |
| 2020 FY | 111.68 Million USD | -5.7% |
| 2020 Q4 | 27.86 Million USD | 0.46% |
| 2020 Q2 | 26.5 Million USD | -10.36% |
| 2020 Q1 | 29.57 Million USD | 11.26% |
| 2019 Q1 | 29.14 Million USD | -3.87% |
| 2019 FY | 118.43 Million USD | 3.45% |
| 2019 Q4 | 26.58 Million USD | -22.23% |
| 2019 Q3 | 34.17 Million USD | 19.78% |
| 2019 Q2 | 28.53 Million USD | -2.09% |
| 2018 Q3 | 28.33 Million USD | -5.92% |
| 2018 FY | 114.48 Million USD | 4.23% |
| 2018 Q4 | 30.31 Million USD | 6.98% |
| 2018 Q2 | 30.12 Million USD | 17.19% |
| 2018 Q1 | 25.7 Million USD | -9.63% |
| 2017 Q4 | 28.44 Million USD | 0.36% |
| 2017 Q3 | 28.33 Million USD | 7.68% |
| 2017 Q2 | 26.31 Million USD | -1.55% |
| 2017 Q1 | 26.73 Million USD | -14.9% |
| 2017 FY | 109.83 Million USD | -8.18% |
| 2016 Q3 | 30.97 Million USD | 5.77% |
| 2016 Q4 | 31.41 Million USD | 1.41% |
| 2016 FY | 119.62 Million USD | -5.45% |
| 2016 Q2 | 29.28 Million USD | 4.78% |
| 2016 Q1 | 27.95 Million USD | -15.4% |
| 2015 Q4 | 33.03 Million USD | 1.1% |
| 2015 Q3 | 32.68 Million USD | 7.91% |
| 2015 Q2 | 30.28 Million USD | -0.76% |
| 2015 Q1 | 30.51 Million USD | 0.0% |
| 2015 FY | 126.51 Million USD | -1.57% |
| 2014 FY | 128.53 Million USD | 95.86% |
| 2014 Q1 | 17.23 Million USD | 0.0% |
| 2013 FY | 65.62 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bionano Genomics, Inc. | 148.99 Million USD | -25.966% |
| Prenetics Global Limited | 60.73 Million USD | -209.006% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -1053.392% |
| CareDx, Inc | 277.76 Million USD | 32.433% |
| Exact Sciences Corporation | 2.06 Billion USD | 90.892% |
| Exagen Inc. | 52.29 Million USD | -258.901% |
| Inotiv, Inc. | 246.9 Million USD | 23.986% |
| Guardant Health, Inc. | 901.62 Million USD | 79.184% |
| Biodesix, Inc. | 77.41 Million USD | -142.421% |
| BioNexus Gene Lab Corp. | 3.92 Million USD | -4683.989% |
| Precipio, Inc. | 13.63 Million USD | -1276.155% |
| iSpecimen Inc. | 16.27 Million USD | -1053.019% |
| Natera, Inc. | 938.98 Million USD | 80.012% |
| Aspira Women's Health Inc. | 24.11 Million USD | -678.303% |
| Standard BioTools Inc. | 113.48 Million USD | -65.373% |
| 23andMe Holding Co. | 420.73 Million USD | 55.392% |
| Castle Biosciences, Inc. | 242.78 Million USD | 22.696% |
| Personalis, Inc. | 128.14 Million USD | -46.46% |
| Aclaris Therapeutics, Inc. | 110.52 Million USD | -69.808% |
| Applied DNA Sciences, Inc. | 16.48 Million USD | -1038.371% |
| OpGen, Inc. | 30.65 Million USD | -512.174% |
| T2 Biosystems, Inc. | 41.49 Million USD | -352.306% |
| Myriad Genetics, Inc. | 600.1 Million USD | 68.725% |
| ICON Public Limited Company | 755.64 Million USD | 75.163% |
| NeoGenomics, Inc. | 341.25 Million USD | 45.003% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -1053.392% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 82.826% |
| RadNet, Inc. | 268.87 Million USD | 30.199% |
| MDxHealth SA | 71.25 Million USD | -163.388% |
| Psychemedics Corporation | 11.33 Million USD | -1555.903% |
| Illumina, Inc. | 3.81 Billion USD | 95.078% |
| Check-Cap Ltd. | 19.28 Million USD | -873.091% |
| Twist Bioscience Corporation | 354.18 Million USD | 47.01% |
| DarioHealth Corp. | 62.17 Million USD | -201.867% |
| Fulgent Genetics, Inc. | 171.9 Million USD | -9.176% |
| Sera Prognostics, Inc. | 39.91 Million USD | -370.176% |
| ENDRA Life Sciences Inc. | 10.52 Million USD | -1683.906% |
| OPKO Health, Inc. | 574.68 Million USD | 67.342% |
| Neogen Corporation | 405.23 Million USD | 53.686% |
| Intelligent Bio Solutions Inc. | 11.7 Million USD | -1502.897% |
| Prenetics Global Limited | 60.73 Million USD | -209.006% |
| Mainz Biomed B.V. | 27.15 Million USD | -591.16% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -2041.282% |
| Trinity Biotech plc | 46.49 Million USD | -303.656% |
| Neuronetics, Inc. | 82.25 Million USD | -128.157% |
| Sotera Health Company | 300.46 Million USD | 37.537% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -2041.282% |